Pricing and Reimbursement in Oncology Payer views [Report Updated: 01012018] Prices from USD $2375
As payer and stakeholder anger mounts, when will the oncology drug price bubble burst?
Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable or winning pharma any friends. In this expert report, US and EU payers note that monopolistic pricing for novel products that represent the only therapeutic option, or the high prices demanded for treatments with minimal therapeutic benefits, cannot always be afforded or justified. Moderate payers are looking to pharma to act, less moderate payers want government intervention and price controls. Pharma risks killing the goose that laid the golden egg and payers warn it's time to get real about cancer drug pricing if pharma wants widespread reimbursement and market access.
Discover on this page...
Why this report is important to you
What the report will enable you to do
Full report contents
Why this report is important to you
Oncological care is an area that has seen some of the steepest spending increases in the past two decades. In 2017, annual spending on anticancer drugs was approximately $100 billion globally, but this figure is predicted to rise to $150 billion by 2020. Some price rises have been triggered by the advent of a more sophisticated understanding of the pathophysiology of cancer, and more effective treatments mean that patients are often living longer and therefore spending on costly therapies puts pressure on the public and private purses. Payers recognise that some highcost hightechnology drugs provide profound patient improvement and, in the wider context of alternative interventions, make commercial sense. But therapies of minimal value, or products priced for rare cancers and then extended to common cancers, are facing mounting resistance. Pharma can no longer hide behind the claim that high prices are needed to pay for overall RD spend and investment many payers see price as driven by nothing more than profit. The ball is in pharma's court to respond and really prove the prices they want represent value.
This report will enable you to...
Understand the diverse pricing and reimbursement environments in the US, UK, France, Germany, Italy and Spain
Deliver the real world data that is supportive of payer decision making
Appraise payer attitudes to innovative contracting and know why payment by results is not universally popular
Know what factors payers would like to see considered when setting prices
Leverage the value biomarkers and companion diagnostics have in gaining payer support
Appreciate the positive influence on payers of headtohead clinical trial studies
Report Contents
Executive summary
Research methodology and objectives
Experts interviewed
Introduction
Pricing and reimbursement in Europe and the US
Cancer drug spend
Pricing and reimbursement mechanisms
Key Insights
Determination of drug price and reimbursement status
Europe
France
Germany
Case study: Opdivo nivolumab
Italy
Spain
United Kingdom UK
Blueteq system in the UK
United States
Factors and evidence that play a role in demonstrating value in payer decisionmaking
Key Insights
Robust data: clinical trial and real world
Cost effectiveness evidence: Health Technology Assessment HTA
Biomarkers and companion diagnostics
Other factors that can influence pricing and reimbursement decisions
Involvement of payers during drug development
Europe
United States
Cost to patient: outofpocket USspecific
Common versus rare cancers
Europe
United States
Financing mechanisms for cancer drugs: payment by results and risksharing agreements
Key Insights
Payment by results
Europe
United States
Value for money with cancer therapies
Key Insights
Justifying the high cost of the newer cancer therapies
Prohibitively high cost cancer drugs: push back or payer acceptance
Pricing a cancer therapy: component parts
Pricing by drug company
Reimbursement decision by payer
High technology has driven price hikes
Patient benefit as a function of cost
Costeffectiveness
Quality of life as a measure of effectiveness
Pricing of cancer drugs compared to other therapeutic areas
Improved patient support financial help programs
Formulating a cancer drug price: component parts
Drive for change in cancer pricing and reimbursement
Key Insights
Challenging high cancer drug prices
The substantial price hike in cancer therapy since 2000
Take home messages
France
Germany
Italy
Spain
United Kingdom
United States
Conclusion
Original Article: Pricing and Reimbursement in Oncology Payer views [Report Updated: 01012018] Prices from USD $2375
NEXT ARTICLE
More From BioPortfolio on "Pricing and Reimbursement in Oncology Payer views [Report Updated: 01012018] Prices from USD $2375"